Business Context and Reporting Period
This Form 8-K Current Report was filed by Mast Therapeutics, Inc. on August 21, 2015. The filing discloses the entry into a material definitive agreement regarding an equity financing program. Note: The request metadata references "Savara Inc," but the filing text explicitly identifies the registrant as "Mast Therapeutics, Inc."
Key Financial Metrics and Transaction Details
- Transaction Type: "At the Market" (ATM) equity offering program.
- Aggregate Offering Price: Up to $30,000,000.
- Sales Agent: Cowen and Company, LLC.
- Commission/Discount: Up to 3.0% of the gross sales price per share.
- Expense Reimbursement: Up to $30,000 for certain expenses incurred by the sales agent.
- Previous Agreement: Supersedes a February 10, 2014 Sales Agreement which had approximately $12.5 million remaining at termination.
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity metrics as this is a transactional report rather than a periodic financial statement.
Material Changes
The primary material change is the termination and superseding of the 2014 Sales Agreement with Cowen and Company, LLC. The new agreement establishes a fresh $30 million capacity for share sales under an effective shelf registration statement on Form S-3 (File No. 333-202960).
Guidance, Outlook, and Risks
- Management Discretion: The Company retains the right to set sales parameters, including share quantity, timing, daily limits, and minimum price floors. The Company may suspend offers and sales at any time.
- Termination Rights: Both the Company and Cowen may terminate the Sales Agreement at any time upon prior written notice.
- Legal Contingencies: The Company has agreed to indemnify and provide contribution to Cowen against certain liabilities, including those under the Securities Act.
- Regulatory Compliance: Sales are subject to applicable state and federal laws and NYSE MKT LLC rules. The report explicitly states it does not constitute an offer to sell in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the current share price and potential dilution impact of selling up to $30 million in shares.
- Review the attached Sales Agreement (Exhibit 10.1) for specific minimum price thresholds and daily volume limits.
- Confirm the status of the $12.5 million remaining under the terminated 2014 agreement to ensure no overlapping obligations exist.
- Monitor future filings for actual sales volumes and proceeds generated under this new ATM program.